Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GOYA DLBCL clinical trial - RNASeq dataset

ABSTRACT: This dataset contains collected RNASeq data of 552 samples from the GOYA clinical trial.

ORGANISM(S): Homo sapiens

PROVIDER: GSE125966 | GEO | 2019/02/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

GOYA DLBCL clinical trial - RNASeq dataset

Project description:GOYA DLBCL clinical trial - RNASeq dataset

| PRJNA518119 | ENA

M16-106 adult and pediatric ALL clinical trial - RNAseq dataset

Project description:M16-106 adult and pediatric ALL clinical trial - RNAseq dataset

| PRJNA683653 | ENA

Gene expression profiling by RNA-seq of newly diagnosed multiple myeloma patients included in the HOVON95 clinical trial

Project description:This gene expression set contains data from patients included in the HOVON95 clinical trial. Using this data the technical comparison between microarray and RNAseq was made.

2022-06-01 | GSE164847 | GEO

Gene expression profiling of newly diagnosed multiple myeloma patients included in the HOVON95 clinical trial

Project description:This gene expression set contains data from patients included in the HOVON95 clinical trial. Using this data the relation between a signature identifying patients with aggressive biology and clinical parameters was studied in newly diagnosed multiple myeloma patients. This dataset was used to identify the relationship between a signature for aggressive disease and clinical parameters.

2022-06-01 | GSE164706 | GEO

RNA sequencing of ATO clinical trial patients

Project description:RNAseq of ATO trial

| PRJEB20631 | ENA

Gene expression profiling of newly diagnosed plasma cell leukemia patients included in the HOVON129 clinical trial

Project description:This gene expression set contains data from patients included in the HOVON129 clinical trial. Using this data the relation between a signature identifying patients with aggressive biology and clinical parameters was studied in newly diagnosed plasma cell leukemia patients. This dataset was used to identify the relationship between a signature for aggressive disease and clinical parameters in plasma cell leukemia.

2022-06-01 | GSE164703 | GEO

M16-106 adult and pediatric ALL clinical trial - RNAseq dataset

Project description:Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may potentiate therapeutic BCL-2 and BCL XL inhibition without dose-limiting thrombocytopenia associated with navitoclax monotherapy. The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase 1 dose escalation study (NCT03181126) in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Forty-seven patients received treatment. A recommended phase 2 dose of 50 mg navitoclax for adults and 25 mg for patients <45 kg with 400 mg adult-equivalent venetoclax was identified. Delayed hematopoietic recovery was the primary safety finding. The complete remission rate was 60%, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy. Thirteen (28%) patients proceeded to transplantation or CAR T-cell therapy on study. Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population.

2021-02-17 | GSE162894 | GEO

Trial

Project description:Trial Trial

| PRJEB7892 | ENA

Gene expression profiling by RNA-seq of newly diagnosed multiple myeloma patients included in the HOVON143 clinical trial

Project description:This gene expression set contains data from patients included in the HOVON143 clinical trial. Using this data the relation between circulating tumor cells and gene expression patterns was studied in newly diagnosed multiple myeloma patients.

2022-06-01 | GSE164830 | GEO

Expression data from 36 KRAS-mutant lung adenocarcinomas from the BATTLE-2 clinical trial.

Project description:In this dataset, we include expression data from 36 KRAS-mutant lung adenocarcinomas from Stage 1 of the BATTLE-2 trial, reflecting patients whose disease has relapsed or progresses following at least one front-line metastatic chemotherapy regimen. Tumor biopsy was performed following informed consent and prior to randomisation to one of the four possible treatment arms.

2015-10-01 | GSE61913 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data